Pharmacopeia — Pharmacopeia Drug Discovery — Investor Presentation (February 2007)
24 slides from Pharmacopeia's investor presentation, Feb 12, 2007

Slide 1: Discovering excellence, driving clinical success
Leslie J. Browne President & CEO New York City February 12th, 2007 Discovering excellence, driving clinical successTM

Slide 2: Forward-Looking Statements
Forward-Looking Statements . This presentation, and oral statements made with respect to information contained in this presentation, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those which e

Slide 3: Value Drivers - Balanced Risk
Value Drivers - Balanced Risk Biopharmaceutical company Focused on cardiovascular and immunological diseases Leader in developing DARA – Phase 1 dosing to start shortly First-in-class dual-acting ARB and endothelin antagonists for kidney disease Deep pipeline of potential blockbusters 6 compounds in

Slide 4: Balancing Risk to Build Value
Balancing Risk to Build Value 8 Million Compound Library Largest in the Industry Integrated HTS Medicinal Chemistry Pharmacology Development GSK Wyeth Organon Cephalon Bristol-Myers Squibb Unique Discovery Platform Strategic Partnerships Proprietary Programs High Value Portfolio Pharmacopeia Value D

Slide 5: Agenda for Today
Agenda for Today Strong sustainable pipeline CXCR2 antagonist in Phase 2 for COPD p38 kinase inhibitors approaching Phase 2 DARA IND submitted December 28th, 2006 Strong strategic partnerships Wyeth R&D agreement on JAK3 GlaxoSmithKline R&D alliance Cephalon advanced discovery partnership Strong fun

Slide 6: One of the Deepest Portfolios in Biotech
Metabolic Disease PS522501 Angiogenesis avb3/avb5 PS388023 Parkinsons Adenosine A2A PS246518 Rheumatoid/MS CCR1 PS375179 Derm/Ocular JAK3 Topical PS608504 Immuno/Inflam JAK3 PS608504 Inflammation PS873266 Respiratory PS948115 Inflammation PS386113 Oncology PS241541 CNS PS778629 Cardiovascular DARA P

Slide 7: Partnered Pipeline Advancing
Partnered Pipeline Advancing Partnered clinical programs advancing CXCR2 antagonist for COPD In Phase 2 Active against biomarker at 50 mg in volunteers Clinical development on-going in COPD p38 kinase inhibitors for RA Approaching Phase 2 Well tolerated in multiple Phase 1 trials Currently in RA pat

Slide 8: Agenda for Today
Agenda for Today Strong sustainable pipeline CXCR2 antagonist in Phase 2 for COPD p38 kinase inhibitors approaching Phase 2 DARA IND submitted December 28th, 2006 Strong strategic partnerships Wyeth R&D agreement on JAK3 GlaxoSmithKline R&D alliance Cephalon advanced discovery partnership Strong fun

Slide 9: DARA – Dual Acting Angiotensin and Endothelin Receptor Antagonist
DARA – First-in-class DARA combines the properties of two marketed cardiovascular product classes in a single compound – Avapro and Tracleer Angiotensin II (Type 1) receptor blockers (ARBs) ETA selective endothelin receptor antagonists (ERAs) DARA’s combination of these activities has the potential

Slide 10: ARB + ERA = Synergistic Combination
ARB + ERA = Synergistic Combination Angiotensin II and Endothelin I Vasoconstriction Tissue proliferation and fibrosis Inflammation Preclinical Results - Resistant Hypertension Potent blockade of endothelin and angiotensin by oral route Potent BP lowering in two preclinical models predictive of acti

Slide 11: PS433540 – Potent as ARB and ERA
PS433540 – Potent as ARB and ERA PS-433540 (DARA) 1.4 > 10,000 BMS-19384 > 10,000 2 Irbesartan (Avapro) Endothelin IC50 (nm, human) Angiotensin IC50 (nm, human) Compound Irbesartan(Avapro®) AT1 antagonist PS-433540 (DARA) AT1 and ETA antagonist BMS-193884 ETA antagonist Angiotensin group Endothelin

Slide 12: Angiotensin and Endothelin Blockade in Vivo
Angiotensin and Endothelin Blockade in Vivo Angiotensin II PS433540 blocks both angiotensin and endothelin in vivo after oral administration in rodents with ED50 = 0.9, 7.6 mpk PS433540 Study PCO-NC-003 ED 50 = 0.9 mg/kg 0 10 20 30 40 50 60 70 80 90 100 Dose (mg/kg) 0.1 1.0 10.0 100.0 Vehicle-adjust

Slide 13: PS433540 – Antihypertensive Activity
PS433540 reduces blood pressure more than Irbesartan (Avapro) at 30 and 100 mmol/kg Effect of Irbesartan and PS433540 on Mean Arterial BP in Spontaneously Hypertensive Rats (SHR) PS433540 – Antihypertensive Activity

Slide 14: New Treatment Options
New Treatment Options Demonstration of antihypertensive effect of PS433540 would support potential benefits in diabetic kidney disease Opportunity for DARA to be an attractive option in resistant hypertension and kidney disease Combine ARB and ERA activity in a single compound, once-a-day pill Avoid

Slide 15: DARA Development Schedule
DARA Development Schedule Complete data and material transfer from BMS 2Q-06 Synthesis of 2 Kg GMP of active ingredient (API) 3Q-06 Pre-IND meeting with FDA 08/15/06 3Q-06 Submit IND 12/28/06 1Q-07 ‘First in man’ dosing 1Q-07 Complete AII challenge study Mid-07 Complete multiple ascending dose study

Slide 16: Early Clinical Evaluation Phase
Early Clinical Evaluation Phase 1 Safety and Pharmacology in Healthy Subjects Establish Safety SAD (Single Ascending Dose) – up to 7 dose levels MAD (Multiple Ascending Dose) – up to 4 dose levels Confirm Dual Activity Mechanism Angiotensin Challenge in Healthy Volunteers Endothelin Challenge in Hea

Slide 17: Agenda for Today
Agenda for Today Strong sustainable pipeline CXCR2 antagonist in Phase 2 for COPD p38 kinase inhibitors approaching Phase 2 DARA IND submitted December 28th, 2006 Strong strategic partnerships Wyeth R&D agreement on JAK3 GlaxoSmithKline R&D alliance Cephalon advanced discovery partnership Strong fun

Slide 18: Strategic Partnerships
Strategic Partnerships Pharmacopeia prosecutes Phase 1 and Phase 2 Non-dilutive tranched funding - $15 million Up to $83 million per program in milestones Double-digit royalties Builds portfolio and clinical infrastructure Late stage optimization programs Upfront $15 million technology access fee Up

Slide 19: Strategic Partnerships
Strategic Partnerships Alliance to develop and commercialize JAK3 Inhibitors for Immunological and Inflammatory Diseases Upfront payment for discovery phase program - $5 million Up to $9MM in research funding over 3 years Up to $175MM in preclinical, clinical and commercialization milestones Double-

Slide 20: Agenda for Today
Agenda for Today Strong sustainable pipeline CXCR2 antagonist in Phase 2 for COPD p38 kinase inhibitors approaching Phase 2 DARA dosing expected to start in Phase 1 shortly Strong strategic partnerships Wyeth R&D agreement on JAK3 GlaxoSmithKline R&D alliance Cephalon advanced discovery partnership

Slide 21: Financial Summary
Financial Summary For the 9-Months Ended September 30, 2006 $13.7 million in net revenue $19.6 million in net loss (including $2.0 million non-cash charge) Cash, Cash Equivalents and Marketable Securities $30.4 million as of December 31, 2005 $31.0 million as of September 30, 2006 Received $20 milli

Slide 22: Stock Information
Stock Information Stock Exchange: NASDAQ Stock Symbol: PCOP Shares Outstanding (10/31/2006): 21.1 million 52- Week Range: $3.56 - $6.51 Market Capitalization (02/08/2007): ~ $95 million Enterprise Value*: ~ $40 million *Calculated on cash and liquid investments as of 09/30/2006 and financing proceed

Slide 23: Pharmacopeia Today
Pharmacopeia Today DARA Phase 1 clinical development First-in-class approach to significant markets Resistant Hypertension Diabetic Nephropathy Dosing in Phase 1 planned to start shortly Partnered clinical programs advancing CXCR2 antagonist in Phase 2 for COPD (partnered with Schering-Plough) p38 k

Slide 24: Discovering excellence, driving clinical success
Discovering excellence, driving clinical successTM
Source: SEC EDGAR · 8-K filed Feb 12, 2007
More decks from Pharmacopeia Inc
Pharmacopeia — Merger or Acquisition (November 2008)34 slides · Nov 3, 2008
The Oppenheimer 19th Annual Healthcare Conference (November 2008)33 slides · Nov 3, 2008
Ligand Pharmaceuticals — Merger or Acquisition (September 2008)18 slides · Sep 24, 2008
BMO Capital Markets 7th Annual Focus on Healthcare Conference 200822 slides · Aug 5, 2008
Investor Presentation (May 2008)36 slides · May 19, 2008
Investor Presentation (May 2008)11 slides · May 16, 2008